Recently, Henlius and Shanghai Pharmaceutical Co., Ltd. (SPH) officially signed a strategic cooperation agreement. Leveraging their respective core strengths in biomedical innovation and full-industry-chain supply chain services, the two parties will deepen resource integration and business collaboration across all dimensions. Through efficient industrial synergy, the partnership aims to enhance access to high-quality medicines, deliver greater service value, and work together toward a healthier future. The signing ceremony was attended by Mr. Yongzhong Li, Executive Director and President of Shanghai Pharmaceuticals; Ms. Lulu Song, Deputy General Manager of SPH; Dr. Jason Zhu, Executive Director and CEO of Henlius; Ms. Nancy Wang, Board Secretary and General Manager of Public Relations; and Ms. Susie Liu, Deputy General Manager of Distribution Management.
Dr. Jason Zhu, Executive Director and CEO of Henlius, stated: “SPH is a key strategic partner for Henlius. This collaboration will integrate the advantages of both sides to create an efficient bridge between R&D innovation and commercial services, closing the 'last mile' from drug development to clinical application. Moving forward, Henlius will continue to prioritize innovative drugs as our core driver and, through deep strategic synergy with partners contribute even greater efforts to improving drug accessibility and benefiting patients.”
Mr. Yongzhong Li, Executive Director and President of Shanghai Pharmaceuticals, commented: “Henlius has consistently pursued innovation-led growth, achieving remarkable results in product development and business expansion. SPH, with its deep roots in the pharmaceutical distribution sector, maintains industry leadership through professional expertise and stable operations. This strategic partnership will elevate our collaboration to a new level of coordinated development. We look forward to leveraging our combined resources to drive the deep integration of Henlius’ R&D innovation with SPH’s commercial platform, bringing more high-quality biologics to patients.”
According to the agreement, the two parties will focus on the industrial transformation of innovative achievements, supported by full-chain commercial operations. The collaboration will center on key areas such as market access, terminal services, and innovative payment models—by optimizing distribution networks, sharing marketing resources, and exploring diversified payment mechanisms to continuously deliver high-quality medical innovations to more patients. Additionally, both sides will actively expand cooperation into frontier areas such as pre-launch commercial planning and international expansion, jointly building a more efficient and sustainable healthcare ecosystem.
Looking ahead, Henlius will remain committed to innovation aligned with industry realities, working closely with partners across the value chain to broaden the scope and deepen the impact of collaborations. By continuously optimizing its product portfolio and operational efficiency, the company aims to build long-term core competitiveness and drive the upgrading and advancement of the biomedical industry.
About SPH
Shanghai Pharmaceutical Co., Ltd. is a national modern pharmaceutical supply chain service enterprise focused on healthcare services. It has grown to become one of China’s largest, most extensively networked and most competitive pharmaceutical enterprises. Building on its national end-market network, the company is committed to advancing hospital supply chain services and forging new industrial advantages. By deepening service innovation and accelerating industrial breakthroughs, the company strives to build a national-level pharmaceutical supply chain service platform.
